# de Sèze

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/de-seze/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,062 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 88 |
| i10-index | 400 |
| Last Known Institution | Hôpital d'Hautepierre |
| OpenAlex ID | https://openalex.org/A5011213325 |
| ORCID iD | https://orcid.org/0000-0002-7197-7578 |
| Works | 1,078 |

## Researcher papers

- [International consensus diagnostic criteria for neuromyelitis optica spectrum disorders](https://scholariq.org/papers/international-consensus-diagnostic-criteria-for-neuromyelitis-optica-spectrum/)
- [Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study](https://scholariq.org/papers/siponimod-versus-placebo-in-secondary-progressive-multiple-sclerosis-expand-a/)
- [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing](https://scholariq.org/papers/mog-encephalomyelitis-international-recommendations-on-diagnosis-and-antibody/)
- [MRI characteristics of neuromyelitis optica spectrum disorder](https://scholariq.org/papers/mri-characteristics-of-neuromyelitis-optica-spectrum-disorder/)
- [Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults](https://scholariq.org/papers/clinical-spectrum-and-prognostic-value-of-cns-mog-autoimmunity-in-adults/)
- [Myelin-oligodendrocyte glycoprotein antibody-associated disease](https://scholariq.org/papers/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/)
- [Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis](https://scholariq.org/papers/clinical-characteristics-and-outcomes-in-patients-with-coronavirus-disease-2019/)
- [MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study](https://scholariq.org/papers/md1003-high-dose-biotin-for-the-treatment-of-progressive-multiple-sclerosis-a/)
- [Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease](https://scholariq.org/papers/clinical-features-and-risk-of-relapse-in-children-and-adults-with-myelin/)
- [Neuromyelitis optica in France](https://scholariq.org/papers/neuromyelitis-optica-in-france/)
- [Immunosuppressive therapy is more effective than interferon in neuromyelitis optica](https://scholariq.org/papers/immunosuppressive-therapy-is-more-effective-than-interferon-in-neuromyelitis/)
- [Aquaporin-4 antibody–negative neuromyelitis optica](https://scholariq.org/papers/aquaporin-4-antibody-negative-neuromyelitis-optica/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Polyomavirus and related diseases](https://scholariq.org/topics/polyomavirus-and-related-diseases/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Hôpital d'Hautepierre](https://scholariq.org/institutions/hopital-d-hautepierre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.